Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CYCN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Hammer Candlestick | Bullish | -5.81% | |
| Stochastic Buy Signal | Bullish | -5.81% | |
| Pocket Pivot | Bullish Swing Setup | -5.81% | |
| Wide Bands | Range Expansion | -5.81% | |
| Oversold Stochastic | Weakness | -5.81% | |
| Wide Bands | Range Expansion | -2.80% | |
| Oversold Stochastic | Weakness | -2.80% | |
| Wide Bands | Range Expansion | -11.64% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 10% | about 15 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Down 5% | about 17 hours ago |
| Down 3% | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 09/27/2019
Cyclerion Therapeutics, Inc. Description
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Diseases Organ Systems Pharmacology Heart Failure Kidney Diseases Orphan Disease Orphan Diseases Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Central Nervous System Diseases Sickle Cell Disease Lung Diseases Heart Failure With Preserved Ejection Fraction
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.96 |
| 52 Week Low | 2.18 |
| Average Volume | 351,166 |
| 200-Day Moving Average | 4.20 |
| 50-Day Moving Average | 3.70 |
| 20-Day Moving Average | 2.96 |
| 10-Day Moving Average | 2.72 |
| Average True Range | 0.29 |
| ADX | 23.31 |
| +DI | 15.00 |
| -DI | 28.32 |
| Chandelier Exit (Long, 3 ATRs ) | 3.60 |
| Chandelier Exit (Short, 3 ATRs ) | 3.18 |
| Upper Bollinger Band | 3.70 |
| Lower Bollinger Band | 2.22 |
| Percent B (%b) | 0.14 |
| BandWidth | 50.03 |
| MACD Line | -0.33 |
| MACD Signal Line | -0.30 |
| MACD Histogram | -0.0261 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.84 | ||||
| Resistance 3 (R3) | 2.84 | 2.71 | 2.77 | ||
| Resistance 2 (R2) | 2.71 | 2.61 | 2.71 | 2.74 | |
| Resistance 1 (R1) | 2.57 | 2.54 | 2.51 | 2.57 | 2.72 |
| Pivot Point | 2.44 | 2.44 | 2.41 | 2.44 | 2.44 |
| Support 1 (S1) | 2.30 | 2.34 | 2.24 | 2.30 | 2.14 |
| Support 2 (S2) | 2.17 | 2.27 | 2.17 | 2.12 | |
| Support 3 (S3) | 2.03 | 2.17 | 2.09 | ||
| Support 4 (S4) | 2.03 |
